Kala Bio (KALA) Common Equity (2016 - 2026)

Kala Bio has disclosed Common Equity across 11 years of filings, most recently posting $9.0 million for Q2 2026.

• In Q2 2026, Common Equity rose 382.1% year-over-year to $9.0 million; the TTM figure through Jun 2026 stood at $9.0 million (up 382.1% YoY), while the FY2025 annual figure was $7.0 million, down 43.27% from the prior year.
• Common Equity came in at $9.0 million for Q2 2026 at Kala Bio, down from $10.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $23.5 million in Q1 2023 to a low of -$31.6 million in Q2 2022.
• Average Common Equity over 5 years is $5.6 million, with a median of $7.2 million recorded in 2023.
• Year-over-year, Common Equity surged 1259.4% in 2023 and slumped 226.33% in 2025.
• Over 5 years, Common Equity stood at $19.0 million in 2022, then slumped by 60.45% to $7.5 million in 2023, then jumped by 64.34% to $12.3 million in 2024, then slumped by 43.27% to $7.0 million in 2025, then grew by 29.27% to $9.0 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $9.0 million in Q2 2026, $10.8 million in Q1 2026, and $7.0 million in Q4 2025.